
Abstract Purpose: To assess whether the interval length between consecutive elective oocyte cryopreservation cycles influences ovarian response and oocyte yield. Methods: This retrospective cohort study included 138 fertility preservation patients who underwent multiple treatment cycles for social indications.. Only patients with at least two treatment cycles were included in the analysis. The interval length between two treatment cycles was obtained and medical charts were reviewed for demographic information and treatment outcomes. The main Outcome Measures were the number and rate of mature oocyte. Results: Treatment outcomes were comparable across short- and long-interval groups. The mean number of mature oocytes retrieved was 6.6 ± 4.0 in the short-interval group and 8.3 ± 5.0 in the long-interval group (p = 0.115). Maturation rates were similar (74% vs. 77%; p = 0.481). Cycle-to-cycle changes in oocyte yield were minimal in the short vs. long-interval groups, respectively: Δ total oocytes: –0.6 ± 4.8 vs. –0.2 ± 4.8; p = 0.714) and Δ maturation rates (–9% ± 44% vs. +5% ± 46%; p = 0.211). Conclusions: Interval duration between consecutive oocyte cryopreservation cycles does not significantly affect oocyte yield or maturation rate. These findings suggest that clinicians may schedule subsequent cycles according to patient preferences and practical considerations rather than physiological constraints.
Abstract Objectives To evaluate the clinical outcomes of high-intensity focused ultrasound (HIFU) ablation in patients with different subtypes of adenomyosis as classified by preoperative magnetic resonance imaging (MRI), and to explore the implications for personalized treatment planning. Design A retrospective cohort study. Participants 447 patients with adenomyosis who underwent HIFU treatment were classified according to the Kishi MRI criteria into Type I (intrinsic, n=195), Type II (extrinsic, n=92), Type III (intramural, n=50), and Type IV (full-thickness, n=110). Methods All 447 patients underwent HIFU ablation under standardized procedural protocols.Treatment parameters, non-perfused volume (NPV) ratio, relief of dysmenorrhea (assessed by NRS score), and improvement in menstrual blood volume (assessed by FPS score) were analyzed and compared across subtypes at 3 and 6 months post-treatment. Results Patients with Type IV adenomyosis had significantly larger lesion volumes and required longer treatment durations with higher energy delivery (p<0.001). The NPV ratio was highest in Type I (74.91% ± 28.34%), followed by Type III (70.34% ± 26.12%), both significantly higher than in Type II (60.01% ± 2.9%) and Type IV (65.93% ± 25.41%) (p<0.05). All subtypes demonstrated significant and sustained improvement in both dysmenorrhea and menorrhagia at follow-up (p<0.05). The comprehensive treatment success rate was highest for Type IV at both 3 (21.82%) and 6 months (27.27%). Limitations This study has several limitations. First, the retrospective design inherently introduces selection bias and limits causal inference. Second,long-term follow-up beyond 6 months was not available, precluding assessment of durability of symptom relief and recurrence rates. Conclusions High-intensity focused ultrasound (HIFU) provides effective symptom relief for all MRI-classified subtypes of adenomyosis. Treatment parameters and efficacy, however, vary by subtype. MRI classification is therefore crucial for guiding treatment and anticipating technical challenges. A personalized approach based on subtype may further optimize therapeutic outcomes.
Objectives: Assisted reproductive technology (ART) demand is increasing, raising questions about the cost-effectiveness of ovarian stimulation (OS) treatments. This study evaluates the clinical and economic outcomes of originator recombinant human follicle-stimulating hormone (r-hFSH-alfa) compared with its biosimilars across multiple ART cycles and countries. Design: A cost-consequence analysis was conducted using a decision-tree model simulating up to four complete OS cycles in women undergoing ART across seven countries (Spain, France, Germany, the United Kingdom, Denmark, Australia, and South Korea). The analysis incorporated both fresh and frozen embryo transfers within each cycle and included base-case and scenario analyses, including treatment-switching strategies. Participants: Theoretical model corresponding to women undergoing ART and receiving originator r-hFSH-alfa or a biosimilar for OS. Methods: Clinical inputs were derived from published real-world data and a meta-analysis. Economic inputs were estimated from public payer perspectives and included drug acquisition, ART procedures, embryo transfer, pregnancy, and delivery costs. Outcomes included cumulative live birth rate (CLBR), total costs, and cost per LB. Base-case and scenario analyses, including treatment-switching strategies, were conducted alongside deterministic sensitivity analyses. Results: Originator r-hFSH-alfa was associated with a higher CLBR compared with biosimilars (58.2% vs 50.8%). This advantage persisted across scenarios and time horizons. Despite slightly higher drug acquisition costs, originator r-hFSH-alfa resulted in lower cost per LB across all countries, with savings ranging from approximately €2,900 to over €8,000 per LB. Strategies initiating treatment with biosimilars were consistently dominated (less effective and more costly) compared to strategies starting with r-hFSH-alpha. Results were robust to sensitivity analyses, with LB rate differences being the primary driver of outcomes. Limitations: This model included limited national clinical data and reliance on modeled assumptions. Other studies are needed to further establish the robustness of the effectiveness data used here. Indirect societal costs and the emotional burden associated with unsuccessful ART cycles were not included. Additionally, costs related to ovarian hyperstimulation syndrome were excluded because rates are very similar between both treatment arms. Conclusions: Across multiple countries and healthcare systems and based on the available effectiveness evidence, initiating ART with originator r-hFSH-alfa improves clinical outcomes and reduces cost per live birth compared with biosimilars. These findings highlight the importance of evaluating ART strategies based on overall treatment pathway value rather than drug acquisition cost alone and support prioritizing more effective treatments in clinical and reimbursement decision-making.
Background: Assisted Reproductive Technologies (ART) such as in-vitro fertilization (IVF) are often reimbursed based on non-medical eligibility criteria, such as patients’ age, marital status, relationship type or reproductive history. These criteria reflect normative assumptions about parenthood and remain ethically contested. Objectives: This study investigates the Belgian public’s awareness of and attitudes toward the use of such non-medical criteria in reimbursing IVF and identifies socio-demographic patterns underlying these views. Methods: A sample of 3,000 adults (18-70y) completed an online survey that elicited attitudes towards public funding of IVF and using funding restrictions based on patients’ age, partner age and gender, relationship type, number of prior children, and different infertility etiologies. Latent class cluster analysis (LCCA) was used to detect opinion subgroups, and logistic regression to assess socio-demographic predictors of subgroup membership. Results: Although there was strong overall support for public reimbursement of IVF, respondents showed limited knowledge about eligibility criteria within the Belgian system. Majorities endorsed several eligibility restrictions, including those based on maternal age (74%), partner age (57%), number of prior biological children (60%), and consciously delayed childbearing (70%). Two thirds opposed prioritizing heterosexual couples. LCCA revealed three distinct opinion profiles (generous, moderately restrictive, and highly restrictive), primarily differentiated by the perceived generosity of current Belgian policy, access for same-sex couples and single mothers, and the acceptability of patient copayments. Parenthood experience and prior infertility were significant predictors of profile membership. Conclusion: This study finds widespread public support for reimbursing fertility treatment within Belgian healthcare, but also for using eligibility criteria that extend beyond the currently used, sole criterion of maternal age. In the light of growing infertility rates, pressured ART budgets and the limited awareness of the current policy observed in this survey, these results underscore the need for further societal debate on priority setting in Belgian infertility care.
Background: Recurrent pregnancy loss (RPL) affects 1%–5% of women worldwide. Advanced maternal age and increasing pre-pregnancy coexisting diseases have complicated its clinical management. Large language models (LLMs) and clinical decision support (CDS) tools are widely used clinically, yet combined use evidence for RPL remains scarce. Objective: To evaluate whether structured CDS materials improve the guideline compliance of three LLMs for standardized RPL clinical scenarios. Design: Comparative simulation study with self-controlled two-stage assessment. Method: Two reproductive medicine specialists developed 25 standard clinical scenarios based on the 2018 and 2022 ESHRE guidelines. Three LLMs (ChatGPT-5.5, Claude-4.8, DeepSeek-R1) were assessed in two phases: baseline evaluation and assessment with structured CDS figures. Response compliance with guidelines was evaluated. Weighted pooled Cohen’s kappa was used to assess inter-rater reliability. The Friedman test with Bonferroni correction was applied for inter-group comparisons, and the Wilcoxon signed-rank test for paired analyses. Results: At baseline, the full guideline compliance rates of the ChatGPT-5.5, Claude-4.8, and DeepSeek-R1 were 44.0%, 28.0%, and 20.0%, with significant differences among groups (P<0.05). After CDS intervention, the rates increased to 92.0%, 84.0%, and 80.0%. All models showed statistically significant improvements (ChatGPT-5.5: P=0.00033; Claude-4.8: P=8.2×10⁻⁵; DeepSeek-R1: P=2.8×10⁻⁵). Dimension-based analysis revealed that all three models achieved a 100% accuracy rate in judging the definition of RPL throughout the study. With the support of CDS tools, their performance in core items, including key screening, etiological, recommended, and non-recommended interventions, was greatly enhanced. No seriously incorrect responses were observed in the whole process. Limitations: This study only included 25 typical clinical scenarios, which is a relatively small sample. In addition, all CDS reference materials were presented in a single unified table format. Conclusion: LLMs only deliver moderate performance in baseline RPL management and are not competent to replace clinical judgment. Combining LLMs with structured CDS tools can remarkably improve the consistency of their outputs with clinical guidelines. This combination can serve as a reliable auxiliary tool for routine RPL clinical work.